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The identification of themolecularmechanisms involved in nicotine addiction and its cognitive consequences is aworldwide priority for
public health. Novel in vivoparadigmswere developed tomatch this aim.Although the2 subunit of the neuronal nicotinic acetylcholine
receptor (nAChR) has been shown to play a crucial role in mediating the reinforcement properties of nicotine, little is known about the
contribution of the different  subunit partners of 2 (i.e., 4 and 6), the homo-pentameric 7, and the brain areas other than the
ventral tegmental area (VTA) involved in nicotine reinforcement. In this study, nicotine (8.7–52.6 g free base/kg/inf) self-
administration was investigated with drug-naive mice deleted (KO) for the 2, 4, 6 and 7 subunit genes, their wild-type (WT)
controls, and KOmice in which the corresponding nAChR subunit was selectively re-expressed using a lentiviral vector (VECmice). We
show thatWTmice,2-VECmice with the2 subunit re-expressed exclusively in the VTA,4-VECmice with selective4 re-expression
in the VTA,6-VECmice with selective6 re-expression in the VTA, and7-KOmice promptly self-administer nicotine intravenously,
whereas 2-KO, 2-VEC in the substantia nigra, 4-KO and 6-KO mice do not respond to nicotine. We thus define the necessary and
sufficient role of42- and62-subunit containing nicotinic receptors (42*- and62*-nAChRs), but not7*-nAChRs, present in
cell bodies of the VTA, and their axons, for systemic nicotine reinforcement in drug-naive mice.
Key words: nicotinic acetylcholine receptor (nAChR); ventral tegmental area (VTA); lentiviral vector; nicotine; intravenous self-admin-
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Introduction
Nicotine is the principal substance responsible for tobacco addic-
tion (Peto et al., 1996; Balfour, 2002; Silagy et al., 2004), but it also
enhances attention and cognitive performance (Newhouse et al.,
2004). Nicotine binds to neuronal nicotinic acetylcholine recep-
tors (nAChRs), a heterogeneous family of pentameric ligand-
gated ion channels (Corringer et al., 2000; Changeux and Edel-
stein, 2005). In the brain, six  (2-7) and/or three  (2-4)
subunits potentially assemble in multiple combinations with a
broad diversity of pharmacological and electrophysiological
properties (McGehee and Role, 1995; Le Nove`re et al., 2002). In
genetically engineered mice lacking the 2 subunit (2-KO
mice), 2 has been shown to contribute to cognitive functions
and nicotine reinforcement (Picciotto et al., 1995, 1998; Granon
et al., 2003). 4 subunit containing nicotinic receptors (4*-
nAChRs) have been implicated in conditioned place preference
for nicotine (Tapper et al., 2004), whereas the role of 6*-
nAChRs remains insufficiently characterized, although both of
them are quantitatively expressed in dopaminergic (DAergic)
neurons (Le Nove`re et al., 1996; Champtiaux et al., 2002, 2003).
The ventral tegmental area (VTA) is considered the principal
brain region mediating the reinforcing properties of multiple
drugs of abuse, including nicotine, but its precise contribution is
still debated (Laviolette and van der Kooy, 2004; Nashmi et al.,
2007).
In the present study we address two important issues: the first
concerns the mode of administration of nicotine. We attempted
to identify the brain regions implicated when nicotine is self-
administered systemically rather than directly injected into the
VTA (Maskos et al., 2005; Besson et al., 2006; David et al., 2006).
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We adopted intravenous nicotine self-administration (SA) be-
cause it is considered the animal paradigm most closely resem-
bling smoking behavior in humans (Rose and Corrigall, 1997;
Corrigall, 1999). In the past, drug SA studies have been con-
ducted using chronic procedures in rodents, in which animals
were used as their own controls (Koob and Weiss, 1990). Re-
cently, studies have been published by several groups using an
acute mouse model in which animals are tested in pairs using a
contingent and a yoked control mouse, which enables rapid as-
sessment of the reinforcing properties of a compound. Although
this acute model is thought to assess the initiation rather than the
chronic maintenance of drug-taking behavior, it was demon-
strated that drug-naive mice acutely self-administer the same
drugs that humans abuse, such as cocaine (Kuzmin et al., 1992,
1996c,d, 2000; Kuzmin and Johansson, 2000; Rasmussen et al.,
2000; Blokhina et al., 2005; Lesscher et al., 2005), morphine
(Kuzmin et al., 1996a, 1997), amphetamine (Cossu et al., 2001),
cannabinoids (Martellotta et al., 1998a), -hydroxybutyric acid
(Martellotta et al., 1998c; Fattore et al., 2000, 2001), scopolamine
(Rasmussen and Fink-Jensen, 2000), and nicotine (Martellotta et
al., 1995; Rasmussen and Swedberg, 1998; Fattore et al., 2002;
Paterson et al., 2003). These studies demonstrated that drug-
naive mice exhibit SA behavior similar to rats chronically trained
under the same schedule of reinforcement (FR1) and using the
same operant response, i.e., nose-poking (Fattore et al., 1999,
2002; Solinas et al., 2003; Spano et al., 2004; Crombag et al.,
2005).
Second, we analyzed the respective roles played by the non-2
subunits expressed in theDAergic system, namely the4,6, and
7 subunits, in the modulation of acute nicotine reinforcement,
and evaluated, using the lentiviral vector technology, to what
extent their presence in the mesolimbic system is required for
nicotine reinforcement. Acute nicotine intravenous SA was per-
formed in drug-naive wild-type (WT) (C57BL/6J) mice, 2-KO,
4-KO, 6-KO, and 7-KOmice, as well as in KOmice with the
corresponding subunit selectively re-expressed in the VTA, and
2-VECmice with selective re-expression in the substantia nigra
(SN).
Materials andMethods
Subjects. Male C57BL/6J (Charles River), 2-, 4-, 6-, 7-nAChR KO
mice and their correspondingWT controls were used, weighing 24–28 g
at the time of experiments. The animals were housed eight per cage with
food and water available ad libitum, kept under standard conditions
(temperature 21  1°C, 60–65% relative humidity) on reversed 12 h
light/dark cycle (light on 7:00 P.M.) and left undisturbed for at least 10
days before starting the experimental procedure. SA sessions took place
during the dark phase of the cycle, between 9:00 and 12:00 A.M. All
experiments were performed in strict accordancewith both theGuide for
the Care and Use of Laboratory Animals (National Institutes of Health)
and the E.C. regulations for animal use in research (CEE n° 86/609).
Lentiviruses. The lentiviral expression vectors are derived from the
pHR’ expression vectors first described by Naldini et al. (1996), with
several subsequent modifications (Maskos et al., 2005). In the lentivi-
ruses used in this study, the bicistronic expression ofmousewild-type2,
4 or 6 nAChR subunit cDNAs and the eGFP cDNA are under the
control of the mouse phosphoglycerate kinase (PGK) promoter (see Fig-
ure 6A). The 2 subunit expressing lentivirus is referred to as
pTRIPU3[PGK_2_IRES2_eGFP_WPRE]. Further details can be
found in Maskos et al. (2005).
To create the pTRIPU3[PGK_4_IRES2_eGFP] construct, a three
step strategy was used. First, on the expression vector containing the
wild-type 4 cDNA, obtained from Jerry Stitzel, the NheI site located
within the 4 cDNA was removed by mutagenesis (QuickChange, Strat-
agene), without affecting amino acid sequence. Second, the modified 4
cDNA was cloned into the pIRES2-eGFP expression plasmid (Clontech)
between XhoI and BamHI of the multiple cloning site using a linker
oligonucleotide NotI /BamHI, creating a NheI site after the 4 stop
codon. Third, the wild-type mouse 4 subunit was finally ligated be-
tween the XhoI-NheI sites of the pTRIPU3[PGK_2_IRES2_
eGFP_WPRE] vector previously described to obtain the complete vector
sequence of 13599 bp (see Fig. 6A).
To construct the pTRIPU3[PGK_6_IRES2_eGFP] construct, a
three-step strategy was used. First, in the expression vector containing
the wild-type6 cDNAplus FLAG sequence, obtained from Ines Ibanez-
Tallon, theClaI restriction site located at the 5 extremity of the4 cDNA
and the XhoI site in the 3 extremity were replaced by mutagenesis
(QuickChange, Stratagene) with XhoI and NheI, respectively. Second,
anothermutagenesis was performed on thismodified vector to introduce
a stop codon between the end of the 6 cDNA and the FLAG sequence.
Third, the wild-typemouse6 subunit cDNAwas finally ligated between
the XhoI-NheI sites of the pTRIPU3[PGK_IRES2_eGFP_WPRE] vec-
tor to replace the 2 cDNA, and to obtain the complete vector sequence
of 13090 bp (see Fig. 6A). All modified regions were verified by DNA
sequencing.
Lentivirus stereotaxic injections.Mice aged 11–13 weeks were anesthe-
tized using 250 l of ketamine 1.5% (Merial)/xylazine 0.05% (Bayer
Healthcare) in PBS. The mouse was introduced into a stereotaxic frame
adapted for use with mice (Cunningham and McKay, 1993). Lentivirus
(2 l at 75 ng of p24 protein per l) was injected bilaterally at: antero-
posterior3.4 mm, lateral 0.5 mm from bregma and4.4 mm from
the surface for VTA injection. To target the SN, injections were at:
antero-posterior3.0 mm (from bregma), lateral 1.3 mm and dorso-
ventral 4.3 mm from the skull, as described by Avale et al. (2008). All
procedures were performed in accordance with European Commission
directives 219/1990 and 220/1990, and approved by Animalerie centrale
andMe´decine du travail, Institut Pasteur. Themice were tested after 5–6
weeks of viral expression.
Drugs. For SA experiments, ()-nicotine bitartrate (Sigma) was
freshly dissolved in 0.9% saline, and the pH adjusted to 7.2  0.1 with
NaOH (0.1N). The drug doses used in this study (8.7, 17.5, 26.3, 35, and
52.6 g/kg/inj) are referred to the free base, and correspond to nicotine
concentrations of 0.025, 0.05, 0.075, 0.1 and 0.15 mg/kg/inj of salt.
Self-administration procedure.Micewere tested in pairs of identical test
cages (8  8  8 cm inner size), each presenting a central frontal hole
(diameter 25mm) 1 cm above the box floor fitted with an infrared sensor
interfaced to an operating computer that controlled an automatic syringe
pump (PHM-100A, Med Associates) (Fig. 1A). A rear vertical chink (5
mm wide) was made on the opposite wall through which the tail was
extended outside the box and taped to a horizontal surface allowing
access to the lateral tail veins with a 27G winged needle (external diam-
eter 0.4 mm), connected to the syringe through Teflon tubing.
Because mice were housed on a reversed light/dark cycle, they were
kept in the dark during transportation from the housing to the experi-
mental room. This room was always the same, exclusively dedicated to
SA experiments in mice, and had the same environmental conditions as
the housing room, i.e., T 21 1°C and 60–65% humidity.
Self-administration sessions were conducted over several seasons, but
care was taken inmaintaining constant room temperature and humidity,
and in ensuring that no sounds entered the experimental room. Experi-
ments were conducted in the dark: a dim light located above the appara-
tus was switched on for incannulation of the tail vein only, whereas the
box containing the animal was coveredwith black cloth so thatmicewere
never exposed to the light. No infrared lighting or other expedients were
used to provide vasodilation of the tail vein or to facilitate needle inser-
tion. No detergents, soap or alcohol were used between sessions, distilled
water only being used to clean boxes at the end of each session.
Animals were first placed in the test cage for 10min of habituation (pre
test) with their tails taped but no needle inserted. Pairs of animals were
selected on the basis of an approximate equal level of nose-poking activ-
ity during pre test. Thereafter, the matched pairs were placed into the
experimental boxes, one mouse defined as active (A) and the other one
passive (P), and needles inserted in the lateral tail vein. Animals were
randomly allocated to the different experimental groups and allowed
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access to the drug under a continuous reinforcement (FR-1) schedule. A
nose-pokingmodus operandiwas used for nicotine SA, because it reflects
a more “natural” behavior for mice and requires less motor and motiva-
tional output than lever-pressing.
Each nose-poke (NP) of the active (A) mouse activated the computer-
operated syringe pump delivering either nicotine or saline infusion (vol-
ume of injection: 1.0 l, infusion time: 1 s) both to the A and the passive
(P) mouse, so that animals received the same amount of the drug simul-
taneously. A white cue light was activated by each NP of the Amouse for
1 s, i.e., during the delivery of the drug, thus serving as a drug-associated
cue along with the noise of the activated syringe pump. No cue light was
activated by NPs of the yoked P mouse.
NPs of the P mouse were recorded but had no scheduled conse-
quences. A short time-out period (i.e., inactivation of NP responses) of
2 s was imposed after each drug infusion. Each treatment included not
5 pairs of animals. SA sessions lasted 30 min and each mouse was used
only once. The number of NPs for both animals (A and P mice) in each
treatment group was analyzed with two-way ANOVA to evaluate effects
of drug delivery mode (“contingently” versus “noncontingently”), unit
dose (including vehicle), and interactions between group and drug dose.
For post hoc comparisons, Dunnett’s test was used to compare single
groups of mice, and respective vehicle controls. Statistical significance
was set at p 0.05. The whole study was designed as a between-subjects
(independent groups) experiment, because each treatment we describe
was performed on a single set of animals.
To obtain gradual measurements of the reinforcing effects of nicotine,
the mean ratio (or Reinforcement Index) R (Kuzmin et al., 1996a,b;
Martellotta et al., 1998a,b) between the number of responses (NPs) of the
active (A) and passive (P) mice during the 30min session was calculated,
nicotine effect being considered rewarding, neutral or aversive when R
was greater than, equal to, or1, respectively.
Receptor autoradiography. Brains from WT, 2-KO, 4-KO, 6-KO,
and re-injected mice were dissected, frozen in dry ice, and stored at
80°C until use. Twenty-micrometer-thick coronal sections were ob-
tained by on a cryostat at 20°C, and thaw mounted on Menzel Gla¨ser
SuperFrost Plusmicroscope slides. Sections were kept at80°C until the
binding assay. Sections used for [ 125I]epibatidine binding were incu-
bated at room temperature with 200 pM [125I]epibatidine (NEN Perkin-
Elmer; specific activity 2200 Ci/mmol) in Tris 50 mM pH 7.4 for 1 h.
Then, sectionswere rinsed twice in the same buffer for 5min, once briefly
in distilled water, and exposed to film. Details of the procedure were
described previously (Zoli et al., 1998).
The [ 125I]conotoxinMII binding procedure was adapted fromWhite-
aker et al. (2000). Sections were preincubated in binding buffer (144 mM
NaCl, 1.5 mMKCl, 2mMCaCl2, 1 mMMgSO4, 20mMHEPES, 0.1% BSA,
pH 6.8)  1 mM PMSF at 25°C for 15 min. Binding reaction was per-
formed in binding buffer supplemented with 0.1% BSA, 5 mM EDTA, 5
mM EGTA, and 10 g/ml aprotinin, leupeptin and pepstatin. The sec-
tions were incubated at 25°C for 2 h with 0.5 nM [125I]conotoxin MII.
Then, sections were rinsed for 30 s once in binding buffer at 25°C, twice
in binding buffer at 4°C, twice in binding buffer diluted 1/10 at 4°C, and
finally once in 5mMHEPES at 4°C. The slides were dried on a slide drying
bench before being exposed for 24 h to Kodak Biomax MS films with
appropriate 125I standards.
Results
Nicotine dose–response curve in C57BL/6J drug-naive mice
The mouse model for acute intravenous SA in drug-naive ani-
mals is schematically presented in Figure 1A. Both the “active”
(A) and the “passive” (P) mouse are in neighboring cages, can-
nulated in the tail vein, and exposed to the same amount of nic-
otine at the same time, determined by the nose-poke behavior of
the A mouse. The procedure was first validated using saline and
nicotine in C57BL/6J mice, which represents the background
strain of WT and KO mice used in this study. The data are pre-
sented both in terms of the number of nose pokes (NP) of the A
and P mouse, and their ratio, the Reinforcement Index, R, see
Materials and Methods.
As shown in Figure 1B, an R value close to 1 implied no
statistically significant difference in the mean number of re-
sponses of A and P C57BL/6J mice when saline (Sal) was made
available (red bar). Conversely, a nicotine concentration of 26.3
g per kg and per infusion (g/kg/inf) significantly increased
responding in the activemice (18.5 1.3), although not affecting
nose-poking activity of yoked passive animals (4.2 2.6), so that
resulting R values were 	1 (red bar). By increasing the R value
above unity, the nicotine concentration of 26.3 g/kg/inf is con-
sidered to possess reinforcing properties. ANOVA analysis con-
firmed highly significant differences in nose-poking activity
among experimental groups (F(7,107)  26.31, p  0.01). Con-
versely, no differences were obtained between active and passive
mice at nicotine concentrations of 8.7, 17.5, 35 and 52.6 g/kg/
inf, with R values being close to 1.
This experiment demonstrated that nicotine exerts a positive
reinforcing effect in C57BL/6J drug-naive mice following a dose-
dependent U-shaped curve, as already reported for nicotine in
DBA mice (Fattore et al., 2002), and for other drugs of abuse
(Martellotta et al., 1998a,b; Ledent et al., 1999; Fattore et al., 2000;
Cossu et al., 2001), under the same experimental conditions.
Absence of nicotine intravenous SA in 2-nAChR KO
drug-naive mice
Figure 2A illustrates nicotine intravenous SA in mice lacking the
2 subunit of the nAChR (2-KO mice). It can be noted that
Figure 1. A, Set-up and simplified scheme for intravenous self-administration experiments.
Each nose-poke of the Active (A) mouse activates a computer-operated syringe pump which
delivers a nicotine injection into the tail vein of both the A and the yoked Passive (P) mouse. B,
Concentration-dependent nicotine intravenous SA in C57BL/6J drug-naive mice. Each bar ( y-
axis at left) represents the mean SEM of the cumulative nose pokes (NPs) of the active mice
(A, black bars) and passive yoked controls (P, white bars) over the 30min session. Each gray bar
( y-axis at right) represents the R value for mice self-administering saline (Sal) or different
nicotine concentrations over the 30 min session. Drug doses are expressed asg/kg/infusion.
**p 0.01 vs yoked passive and saline groups. ANOVA followed by Dunnett’s test (n 12–18
pairs of animals). ***p0.001 vs saline control group. ANOVA followedbyDunnett’s test (n
12–18 pairs of animals).
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when saline infusions (Sal) were made contingent on nose-
poking activity, the R value was close to 1, indicating no statisti-
cally significant difference in the mean number of NPs between
active and passive 2-KO mice (Fig. 2A, right). Yet, unlike
C57BL/6J mice (Fig. 1B) and WT mice (Fig. 2A, left), active
2-KO animals to which free access to nicotine was given at the
dose of 26.3 g/kg/inf did not increase their rate of responding
with respect to either passive animals receiving noncontingent
nicotine infusions or control animals receiving contingent vehi-
cle (saline) infusions (F(3,29)  1.39, ns). All of the doses tested
were ineffective in inducing nicotine SA behavior in2-KOmice,
so that the reinforcement index (R) was equivalent to 1 (Fig. 2A,
right).
Recovery of nicotine intravenous SA
after re-expression of 2 in the VTA but
not the SN of2-KO mice
As shown in Figure 2B, when saline was
made contingent on NP responses of VTA
re-expressed 2-KO mice (2-VEC-
VTA), active and passive animals dis-
played a similar mean number of re-
sponses, as indicated by the R value (gray
bar). However, whenmice were allowed to
intravenously self-administer nicotine at
26.3 g/kg/inf (black bars), active mice
significantly increased their rate of nose-
poking activity with respect to both yoked
passive mice (white bars) receiving nico-
tine noncontingently, and controlmice re-
ceiving saline (Sal). Accordingly, the nico-
tine concentration of 26.3 g/kg/inf
increased R above unity (gray bar), and an
overall significant effect of drug was re-
vealed by post hoc comparisons (F(3,21) 
10.74, p 0.01). Nicotine thus exerts pos-
itive reinforcing effects in VTA re-
expressed 2-KO mice, where it is able to
sustain acute SA behavior.
In another set of mice, the 2 subunit
was selectively re-expressed in the sub-
stantia nigra (2-VEC-SN) and the mice
tested under the same conditions. As
shown in Figure 2C, nicotine at 26.3 g/
kg/inf did not modify the R index (gray
bar) with respect to saline (Sal), thus
showing no intravenous nicotine SA at this
unit nicotine dose. Lower and higher con-
centrations of 17.5 and 35 g/kg/inf, re-
spectively, did not result in nicotine SA as
well, thus proving absence of any shift in
the dose–response curve. Nicotine thus
exerts positive reinforcing effects only
when the2-subunit is re-expressed in the
VTA, but not in the SN.
Identifying the role played by
homomeric7*-nAChRs in the VTA
The 7*-nAChRs in the VTA have been
described to modulate the discharge pat-
tern of DA neurons (Mameli-Engvall et
al., 2006) and to mediate long-term ef-
fects of chronic exposure to nicotine
(Besson et al., 2007). McGehee and
Mansvelder had also established their importance for nicotine
induced LTP in the VTA (Mansvelder and McGehee, 2000;
Mansvelder et al., 2002).
Their role was thus tested in acute nicotine SA. As shown in
Figure 3, we found that, as in the2-WT andVTA-VECmice, the
only effective dose of nicotine in sustaining SA behavior was 26.3
g/kg/inf, the only nicotine concentration significantly increas-
ing R	1 (gray bar). Under these conditions, both 7-WT (left)
and 7-KO (right) active mice (black bars) displayed a robust
increase in NP numbers over saline (Sal) controls and over the
corresponding passive mice (white bars), thus showing that the
lack of 7-subunit does not interfere with the acute rewarding
effects of nicotine.
Figure2. A, Nicotine intravenousSA in2-nAChRknock-out (KO) andwild-type (WT)mice. Eachbar ( y-axis at left) represents
themean SEMof the cumulative nosepokes (NPs) of the2-WT (left) and2-KO (right) activemice (A, black bars) andpassive
yoked controls (P, white bars) over the 30min session. Each gray bar ( y-axis at right) represents the R value for2-WT (left) and
2-KO (right) mice self-administering nicotine over the 30 min session. Doses are expressed asg/kg/inf. #p 0.05 vs corre-
sponding saline group and **p 0.01 vs corresponding yoked passive group. ANOVA followedbyDunnett’s test (n 7–13pairs
of animals). ***p 0.001 vs corresponding saline group. ANOVA followed by Dunnett’s test (n 7–13 pairs of animals). B,
Nicotine intravenous SA in ventral tegmental area (VTA) re-expressed2-KO mice (2-VEC-VTA mice). Each bar ( y-axis at left)
represents themean SEM of the cumulative nose pokes (NPs) of the2-VEC-VTA activemice (A, black bars) and passive yoked
controls (P, white bars) over the 30 min session. Each gray bar ( y-axis at right) represents the R value for 2-VEC-VTA mice
self-administering saline (Sal) or nicotine over the 30min session. Doses are expressed asg/kg/inf. **p 0.01 vs yokedpassive
mice and saline controls. ANOVA followedbyDunnett’s test (n6–8pairs of animals). *p0.05 vs saline control group.ANOVA
followed by Dunnett’s test (n 6–8 pairs of animals). C, Nicotine intravenous SA in substantia nigra (SN) re-expressed2-KO
mice (2-VEC-SN mice). Each bar ( y-axis at left) represents the mean  SEM of the cumulative nose pokes (NPs) of the
2-VEC-SN active mice (A, black bars) and passive yoked controls (P, white bars) over the 30 min session (n 6–14 pairs of
animals). Each gray bar ( y-axis at right) represents the R value for2-VEC-SNmice self-administering saline (Sal) or nicotine over
the 30 min session. Doses are expressed asg/kg/inf (n 6–14 pairs of animals).
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The role played by the4 subunit partner of2 in the VTA
The 4 subunit is among the main partners of the 2 subunit,
coexpressed in DAergic and GABAergic neurons of the VTA
(Klink et al., 2001; Champtiaux et al., 2002, 2003). Mice deleted
for the 4 subunit and their corresponding WT littermates were
therefore tested for nicotine reinforcement at the same doses as
for the 2-KO mice. As shown in Figure 4A, 4-WT mice (left)
exhibited a U-shaped dose–response curve for nicotine. Yet, as
for 2-KO animals, 4-KO animals (right) did not reveal R val-
ues significantly different from1 (gray bars), showing the absence
of nicotine reinforcement at all of the doses tested.
A lentivirus was then constructed expressing the 4-subunit
(see Fig. 6A). As shown in Figure 4B, nicotine reinforcement was
promptly restored by selective re-expression of the 4 subunit in
the VTA, a nicotine concentration of 26.3g/kg/inf being able to
increase the R value 	1 (gray bar). Along with previous results
from experiments with 2-VEC-VTA mice, these data highlight
the critical role played by the 42* containing subtype of
nAChRs in mediating the acute reinforcing properties of
nicotine.
The role played by the6 subunit in the VTA
This subunit has generated substantial interest since its original
description because of its differential expression in the DAergic
system, and its role in locomotion (Le Nove`re et al., 1996, 1999).
Yet, 6-KO animals did not show any overt developmental, neu-
rological or behavioral deficits (Champtiaux et al., 2002, 2003).
However, when tested in our SA paradigm, although 6-WT
animals (left) did self-administer nicotine at the unit dose of 26.3
g/kg/inf, 6-KO drug-naive mice (right) did not do so, as illus-
trated in Figure 5A. The 6-KO did not self-administer nicotine
even within an extensive range of lower (8.7–17.5 g/kg/inf) or
higher (35–52.6 g/kg/inf) doses, showing R values close to 1
(gray bars). This finding provides the first behavioral phenotypes
identified so far in the 6-KO line.
The 6 subunit was then selectively re-expressed using a len-
tiviral vector (Fig. 6A) in the VTA of 6-KO mice (Fig. 6B) and
the mice tested under the same conditions. Active mice (black
bars) significantly ( p 0.01) increased their rate of nose-poking
for nicotine at 26.3 g/kg/inf with respect to their yoked passive
mice (white bars), and the R value was therefore	1, as indicated
in Figure 5B (gray bars). Conversely, active and passive 6-VEC-
VTA mice displayed a similar mean number of responses when
either saline (Sal) or nicotine at 17.5 and 35g/kg/inf were made
contingent on NP responses. Nicotine thus exerts positive rein-
forcing effects in VTA re-expressed 6-KO mice, where it is able
to sustain acute SA behavior. This experiment demonstrates that
62* nAChRs in the VTA and/or in its projections are necessary
and sufficient to establish nicotine SA behavior.
Verifying the injection sites in VEC mice
Figure 6B illustrates representative samples of specific ligand
binding experiments performed onWT, KO andVECmice, cov-
ering the different genotypes and injection paradigms. In the
upper part of the figure, binding of iodinated epibatidine reveals
the lack of high affinity binding sites in 2 and 4 KO mice,
whereas these are restored in the corresponding vectorised mice.
As shown before for 2 injection into the SN (Avale et al., 2008),
2 re-expression in the SN yields a strong signal in the area of the
SN pars compacta, sparing the VTA.
In the lower part, binding of iodinated conotoxin MII was
performed to identify 6*-nAChRs. In 6-KO mice no specific
signal was obtained in the VTA, whereas a strong signal was vis-
ible in WT mice, and in VECmice.
Discussion
We have developed a robust, reproducible method for intrave-
nous nicotine self-administration in drug-naivemice and applied
it to a detailed study of the role of homo- and heteropentameric
nAChRs in this acute paradigm. The method is robust because it
was performed in different seasons, over a couple of years, and
yielded reproducible results as demonstrated by the comparable
data obtained with WT mice of the different KO strains. In the
Materials and Methods section we have identified key issues re-
quired, like a reversed light/dark cycle, carrying out experiments
in the dark, and “nose-poking” rather than “lever-pressing” as
modus operandi. Because lever-pressing activity requires more
motor and motivational output than nose-poking, it likely may
prove to be a less “natural” behavior for mice, and therefore not
be the most suitable to unmask behavioral differences in drug-
taking behavior.
Our work demonstrates first of all that, in line with previous
studies, drug-naive C57BL/6J mice are sensitive to nicotine’s re-
inforcing effects (Robinson et al., 1996; Stolerman et al., 1999).
They display a typical inverted U-shaped dose–response curve to
intravenous nicotine, as observed in two previous studies (Fat-
tore et al., 2002; Paterson et al., 2003). Moreover, in agreement
with the data of Paterson et al. (2003), a sharp dose–response
curve was obtained, and a dose of 26.3 g/kg/inf was confirmed
as being the only reinforcing one in sustaining acute SA behavior
(Rasmussen and Swedberg, 1998). These findings, that only one
specific dose of nicotine is able to sustain SA behavior, are remi-
niscent of human studies in which adult smokers clearly titrate
their nicotine intake carefully to experience the positive effects of
the drug (Benowitz and Jacob, 1985; Benowitz, 2001). Similarly,
adolescent smokers do titrate their nicotine intake in response to
smoking low yield cigarettes by taking more puffs per cigarette
(Kassel et al., 2007).
Also in line with previous studies, 2-KO mice no longer
self-administer nicotine intravenously (Picciotto et al., 1998), or
Figure 3. Nicotine intravenous SA in 7-nAChR KO and WT mice. Each bar ( y-axis at left)
represents themean SEMof the cumulative nose pokes (NPs) of the7-WT (left) and7-KO
(right) active mice (A, black bars) and passive yoked controls (P, white bars) over the 30 min
session. Each gray bar ( y-axis at right) represents the R value for 7-WT (left) and 7-KO
(right) mice self-administering saline (Sal) or nicotine over the 30 min session. Doses are ex-
pressed asg/kg/inf. #p 0.05 vs corresponding saline group and **p 0.01 vs correspond-
ing yokedpassive group. ANOVA followedbyDunnett’s test (n 6–8pairs of animals). **p
0.01 and ***p 0.001 vs corresponding saline group. ANOVA followed by Dunnett’s test (n
6–8 pairs of animals).
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into the VTA (Maskos et al., 2005). In addition, the data obtained
with 2-VEC-VTAmice are consistent with the observation that
nicotine increases the burst firing of VTA DAergic neurons
(Grenhoff et al., 1986; Mameli-Engvall et al., 2006), decreases
electrical self-stimulation in the VTA (Ivanova and Greenshaw,
1997), anddose-dependently enhancesDA releasewhenperfused
into the VTA (Tizabi et al., 2002; Rahman et al., 2004). Accord-
ingly, infusion of nicotinic antagonist into the VTA significantly
decreases nicotine SA in the rat (Corrigall et al., 1994).
Moreover, re-expression of the 2 subunit in the SN pars
compacta (Avale et al., 2008) instead of the VTA of 2-KO mice
did not yield any nicotine SA. The present study thus unequivo-
cally identifies the presence of the nAChR 2 subunit in the VTA
as the critical condition for nicotine intra-
venous SA in drug-naive animals. Consis-
tent with this conclusion, nicotine SA is
altered by lesions of the posterior portion
of the pedunculopontine tegmental nu-
cleus, which innervates VTADAergic neu-
rons, but not by lesions of the anterior re-
gion projecting to SN pars compacta
(Alderson et al., 2006). Yet, additional
brain structures such as the central linear
nucleus raphe´, located posterodorsally to
the VTA, and the supramammilary nu-
cleus of the posterior hypothalamus, lo-
cated anterior to the VTA, may also con-
tribute to the primary reinforcing effects
of nicotine, at least in the rat (Ikemoto et
al., 2006). Findings from the present study
also demonstrate that drug-naive 7-KO
mice do self-administer nicotine in aman-
ner indistinguishable from their WT
counterparts. This finding is consistent
with the pharmacological evidence that
the 7 subunit is not involved in chronic
nicotine SA in trained rats (Grottick et al.,
2000), nor in nicotine-induced condi-
tioned place preference (Walters et al.,
2006). Recent work (Besson et al., 2007;
Salas et al., 2007) suggests that 7*-
nAChRs play a key role in long-term adap-
tations to passive chronic nicotine, rather
than in the short-term response to nico-
tine SA.
These in vivo data also invite compari-
son with the work of McGehee and Mans-
velder performed in slices (Mansvelder
and McGehee, 2000; Mansvelder et al.,
2002). They could show that short applica-
tion of nicotine leads to the desensitization
of heteromeric receptors on both the
GABAergic and DAergic neurons in the
VTA. Because 7*-nAChRs on glutama-
tergic axons in the VTA do not desensitize,
the net effect is an increased glutamatergic
stimulation of theDAneurons in theVTA,
explaining the increase in DA cell firing.
This increase in elicited DA release is then
considered the key step in nicotine rein-
forcement. It is difficult here to extrapolate
from these in vitro studies to our acute re-
inforcement paradigm. In slices, impor-
tant afferents, like the cholinergic input from the mesopontine
tegmentum, as discussed above (Alderson et al., 2006), get sev-
ered. Our in vivo work suggests that this 7*-nAChR mediated
effect is not crucial for nicotine SA in an acute paradigm, and we
also been able to establish recently that 7-KOmice exhibit only
a slightly altered electrophysiological response to nicotine injec-
tionwhenDAergic neurons are recorded in vivo (Mameli-Engvall
et al., 2006).
The 4 subunit partner of the 2 subunit has also been impli-
cated in reward: selective activation of 4*-nAChRs by low doses
of nicotine that do not activate other nAChR subtypes has been
reported to be sufficient for nicotine-induced reward, as tested by
conditioned place preference (Tapper et al., 2004). Consistent
Figure4. A, Nicotine intravenous SA in4-nAChRKOandWTmice. Eachbar ( y-axis at left) represents themean SEMof the
cumulativenosepokes (NPs) of the4-WT (left) and4-KO (right) activemice (A, blackbars) andpassive yoked controls (P,white
bars) over the 30min session. Each gray bar represents R value for4-WT (left) and4-KO (right)mice self-administering saline
(Sal) nicotineover the30min session.Doses are expressedasg/kg/inf. **p0.01vs correspondingyokedpassive and/or saline
groups. ANOVA followed by Dunnett’s test (n 5–14 pairs of animals). **p 0.01 vs corresponding saline group. ANOVA
followedbyDunnett’s test (n5–14pairs of animals).B, Nicotine intravenous SA inVTA re-expressed4-KOmice (4-VEC-VTA
mice). Each bar ( y-axis at left) represents themean SEMof the cumulative nose pokes (NPs) of the4-VEC-VTA activemice (A,
blackbars) andpassive yoked controls (P,whitebars) over the30min session. Eachgraybar ( y-axis at right) represents theRvalue
for4-VEC-VTAmice self-administering saline (white bar) or nicotine (black bars) over the 30min session. Doses are expressed as
g/kg/inf. **p 0.01 vs corresponding saline group. ANOVA followed by Dunnett’s test (n 6–10 pairs of animals). **p
0.01 vs saline control group. ANOVA followed by Dunnett’s test (n 6–10 pairs of animals).
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with this view, 4-KO mice did not show
significant nicotine SA and this behavior
was promptly restored only after the tar-
geted re-expression of the 4 subunit in
the VTA. 42*-nAChRs are thus major
players in acute nicotine SA in drug-naive
mice.
A rather surprising result of our study is
the loss of nicotine SA in6-KOmice. The
6 subunit is to a large extent coexpressed
with the 4 subunit in DAergic neurons of
the VTA. 42*-, 62*-, and 462*-
nAChRs have been found enriched in the
terminal fields of these neurons in the Nu-
cleus accumbens (NuAcc) (Champtiaux et
al., 2003; Salminen et al., 2007). We thus
demonstrate that 6*-nAChRs cannot
compensate for the absence of the 4 sub-
unit, and vice versa, although both are
widely expressed in VTA neurons. Impor-
tantly, targeted re-expression of the 6
subunit in the VTA of 6-KO mice
promptly restored nicotine SA behavior,
confirming the VTA as the key area in me-
diating nicotine reinforcement.
Our in vivo findings can be seen as a
behavioral correlate of recent in vitrowork
using fast-scan cyclic voltammetry in slices
of mouse NuAcc (Exley et al., 2008). This
study indeed showed that -conotoxin
MII, a specific antagonist of 6*-nAChRs,
selectively suppressed DA release evoked
by single and low-frequency action poten-
tials, whereas DA release was potently en-
hanced by high-frequency bursts. This fil-
tering effect, previously described for
nicotine (Rice andCragg, 2004; Zhang and
Sulzer, 2004), is considered the key event
in the establishment of saliency of
nicotine-associated cues. In this paradigm,
6*-nAChRs therefore dominate the con-
trol of DA neurotransmission, when nico-
tine is applied to the slice. Our in vivo re-
sults on 4-KO and 6-KO mice together
with the in vitro study of Exley et al. (2008)
thus highlight the crucial role of 4* and
6*-nAChRs in nicotine reinforcement.
Our re-expression technique targets
both DA and GABAergic neurons in the
VTA (Maskos et al., 2005), such that both
transmitter systems have their nAChRs restored in theVECmice.
Thus the questions remains as to the relative importance of
nAChRs in GABA vs DA neurons for the SA behavior measured
here. McGehee and Mansvelder have shown that heteromeric
nicotinic receptors play a role in both neurotransmitters systems
of the VTA (Mansvelder and McGehee, 2000; Mansvelder et al.,
2002) for the increase in DA cell firing, and consequently DA
release, considered the key step in the reinforcing effects of a
drug. It would thus be interesting to further dissect the action of
nicotine in the VTA with respect to neurotransmitter subtype.
This issue can be addressed by the selective targeting of nAChRs
to GABAergic and DA cells using lentiviral vectors with specific
promoters. This work is currently under way (Tolu et al., 2007).
In conclusion, we have demonstrated that the presence of the
2, 4, and 6 subunits in cell bodies of the VTA and their
corresponding mesolimbic terminals is necessary and sufficient
for acute intravenous SA of a pharmacological dose of nicotine. It
is thus tempting to speculate that a specific 462*-nAChR is
the keymediator of intravenous SA. This hypothesis can be tested
once FRET experiments using tagged nicotinic subunits will be-
come possible in vivo (Nashmi et al., 2003;Drenan et al., 2008), to
prove the presence and identify the functional properties of a
given subunit combination.
On the contrary, the7 subunit is not involved inmediating the
acute reinforcing properties of nicotine. These findings illustrate the
Figure5. A, Nicotine intravenous SA in6-nAChRKOandWTmice. Eachbar ( y-axis at left) represents themean SEMof the
cumulativenosepokes (NPs) of the6-WT (left) and6-KO (right) activemice (A, blackbars) andpassive yoked controls (P,white
bars) over the 30 min session. Each gray bar ( y-axis at right) represents the R value for 6-WT (left) and 6-KO (right) mice
self-administering saline (Sal) or nicotine over the 30min session. Doses are expressed asg/kg/inf. #p 0.05 vs corresponding
saline group and **p 0.01 vs corresponding yoked passive or saline control groups. ANOVA followed by Dunnett’s test (n
6–8pairs of animals). **p 0.01 vs corresponding saline group. ANOVA followed byDunnett’s test (n 6–8pairs of animals).
B, Nicotine intravenous SA in VTA re-expressed6-KOmice (6-VEC-VTAmice). Each bar ( y-axis at left) represents themean
SEMof the cumulativenosepokes (NPs) of theactivemice (A, blackbars) andpassive yoked controls (P,whitebars) over the30min
session. Each gray bar ( y-axis at right) represents the R value for6-VEC-VTAmice self-administering saline (Sal) or nicotine over
the 30min session. Doses are expressed asg/kg/inf. ##p 0.001 vs corresponding saline group and **p 0.01 vs correspond-
ing yoked passive or saline control groups. ANOVA followed by Dunnett’s test (n 9–11 pairs of animals). **p 0.01 vs saline
controls. ANOVA followed by Dunnett’s test (n 9–11 pairs of animals).
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validity of this new powerful experimental paradigm for a detailed
in-depth genetic analysis of nicotine reinforcement in the mouse.
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